A-Alpha Bio Announces Collaboration with Bristol Myers Squibb to Discover Molecular Glue Targets for Protein Degradation
We’re excited to announce our collaboration with Bristol Myers Squibb (BMS) to discover molecular glue targets for protein degradation.
Targeted protein degradation is an emerging therapeutic modality enabling therapeutic intervention otherwise complex with conventional approaches. We will identify and characterize novel pairs of E3 ubiquitin ligases and targets for BMS to use for the potential design and development of molecular glues to induce targeted protein degradation. Our proprietary platform, AlphaSeq, is uniquely suited to detect weak protein-protein interactions that allow the engineered discovery of molecular glues.
We are delighted to collaborate with the BMS team in this emerging therapeutic modality.
Coverage in BioCentury can be read here.
Coverage in MedCity News can be read here.